Research And Development
Europe
Health
AstraZeneca
$39.149876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$39.14
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.36 (0.93%) Today
+$0.11 (0.29%) After Hours
Why Robinhood?
You can buy or sell AstraZeneca and other stocks, options, ETFs, and crypto commission-free!
About
AstraZeneca PLC, also called AstraZeneca, is a holding company, which engages in the research, development and manufacturing of pharmaceutical products. The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases. Read More Its pipeline consists of azd 4831, azd 8601, medi 6012, tagrisso bloom, durvalumab, selumetinib, lyparza polo, epanova, farxiga and brilinta. The company distributes its products under the following brands: Atacand, Crestor, Onglyza, Nexium, Entocort, Losec, Merrem/Meronem, Carbocaine, Citanest, Diprivan, Marcaine/Sensorcaine. AstraZeneca was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Employees
64,400
Headquarters
Cambridge, Cambridgeshire
Founded
1992
Market Cap
98.95B
Price-Earnings Ratio
41.16
Dividend Yield
3.61
Average Volume
4.58M
High Today
$39.32
Low Today
$38.91
Open Price
$39.01
Volume
1.34M
52 Week High
$43.30
52 Week Low
$34.38
Collections
Research And Development
Europe
Health
Manufacturing
Cancer Prevention
Biotechnology
Medical
Biopharmaceutical
News
Seeking AlphaMay 21
An FDA Win For AstraZeneca Shifts To An Expanded Label In The Type 2 Diabetes Market
AstraZeneca (AZN) announced that it had received approval for Qternmet XR as an oral adjunct treatment to diet and exercise for glycemic control in adults with type 2 diabetes (T2D). This is good news for the company because it has already received approval for a doublet therapy for the very same patient population.
MarketWatchMay 20
Drugmakers’ lobbying spending at 10-year high as Washington targets soaring prices
As Washington aims to rein in soaring drug prices, the spending by the industry’s main trade group and seven key drugmakers has climbed to a level not seen in a decade.
Seeking AlphaMay 20
AstraZeneca's Symbicort Turbuhaler shows value proposition in real-world asthma study
New data from Novel START, an open-label real-world study of AstraZeneca's (NYSE:AZN) Symbicort Turbuhaler (budesonide/formoterol) in patients with mild asthma showed a treatment advantage compared to two commonly used regimens.
Price Paid on Robinhood
10% Higher
Right Now
52 Week Low
$34.38
Average Price Paid
$35.60
52 Week High
$43.30
Earnings
$0.29
$0.72
$1.15
$1.58
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
$0.89 per share